Pelthos Therapeutics Inc. (PTHS)

Market Cap	105.54M
Revenue (ttm)	n/a
Net Income (ttm)	-9.04M
Shares Out	3.07M
EPS (ttm)	-14.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,928
Open	37.14
Previous Close	37.42
Day's Range	30.68 - 37.14
52-Week Range	4.50 - 54.29
Beta	n/a
Analysts	Buy
Price Target	50.00 (+45.35%)
Earnings Date	Nov 13, 2025

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 11
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTHS
• Website: https://pelthos.com

Analyst Summary

According to one analyst, the rating for PTHS stock is "Buy" and the 12-month stock price target is $50.0.

Price Target

$50.0

(45.35% upside)

Analyst Consensus: Buy